"Nevertheless, research has proven that a higher incidence of breast cancer tumours can occur in women receiving therapies that involve a combination of the natural component estrogen and the synthetic progestin," explained Salman Hyder, the Zalk Endowed professor in tumour angiogenesis and professor of biomedical sciences.
Most older women normally have benign lesions in breast tissue. These lesions typically don't form tumors until they receive the 'trigger' -- in this case progestin - that attracts blood vessels to cells essentially feeding these lesions causing them to expand. The new study shows that when the supplement luteolin is administered to human breast cancer cells in the lab, benefits can be observed including reduction in those vessels "feeding" the cancer cells.
The early-stage results of this research are promising.
"If additional studies are successful within the next few years, the university officials will request authority from the federal government to begin human drug development.
The research was published in the journal Springer Plus.